Jonathan Chang
Stock Analyst at Leerink Partners
(0.62)
# 3,677
Out of 4,748 analysts
91
Total ratings
29.17%
Success rate
-19.83%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Jonathan Chang
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| VINC Vincerx Pharma | Maintains: Outperform | $4 → $2 | $1.56 | +28.21% | 6 | Oct 8, 2024 | |
| IMCR Immunocore Holdings | Initiates: Outperform | $74 | $31.64 | +133.88% | 1 | Apr 29, 2024 | |
| NBTX Nanobiotix | Initiates: Outperform | $11 | $3.46 | +217.92% | 1 | Dec 8, 2023 | |
| NVCR NovoCure | Initiates: Outperform | $51 | $25.52 | +99.84% | 1 | Aug 4, 2023 | |
| KPTI Karyopharm Therapeutics | Maintains: Market Perform | $6 → $5 | $0.66 | +657.12% | 12 | Jan 10, 2023 | |
| REPL Replimune Group | Maintains: Outperform | $30 → $34 | $14.07 | +141.65% | 9 | Dec 7, 2022 | |
| GMAB Genmab | Maintains: Market Perform | $31 → $33 | $19.85 | +66.25% | 9 | Nov 10, 2022 | |
| BCYC Bicycle Therapeutics | Maintains: Outperform | $48 → $50 | $12.98 | +285.21% | 4 | Aug 22, 2022 | |
| RVMD Revolution Medicines | Maintains: Outperform | $31 → $30 | $40.92 | -26.69% | 4 | Aug 10, 2022 | |
| MGNX MacroGenics | Maintains: Outperform | $15 → $12 | $3.03 | +296.04% | 8 | Aug 9, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $13 → $14 | $0.59 | +2,285.01% | 5 | Aug 9, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $25 → $26 | $5.33 | +387.80% | 5 | Jun 3, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $101 → $95 | $27.24 | +248.75% | 8 | May 11, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Market Perform | $2 → $3 | $0.58 | +415.02% | 8 | May 9, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $41 → $28 | $7.69 | +264.11% | 3 | Feb 25, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $57 → $53 | $18.83 | +181.47% | 7 | Aug 5, 2021 |
Vincerx Pharma
Oct 8, 2024
Maintains: Outperform
Price Target: $4 → $2
Current: $1.56
Upside: +28.21%
Immunocore Holdings
Apr 29, 2024
Initiates: Outperform
Price Target: $74
Current: $31.64
Upside: +133.88%
Nanobiotix
Dec 8, 2023
Initiates: Outperform
Price Target: $11
Current: $3.46
Upside: +217.92%
NovoCure
Aug 4, 2023
Initiates: Outperform
Price Target: $51
Current: $25.52
Upside: +99.84%
Karyopharm Therapeutics
Jan 10, 2023
Maintains: Market Perform
Price Target: $6 → $5
Current: $0.66
Upside: +657.12%
Replimune Group
Dec 7, 2022
Maintains: Outperform
Price Target: $30 → $34
Current: $14.07
Upside: +141.65%
Genmab
Nov 10, 2022
Maintains: Market Perform
Price Target: $31 → $33
Current: $19.85
Upside: +66.25%
Bicycle Therapeutics
Aug 22, 2022
Maintains: Outperform
Price Target: $48 → $50
Current: $12.98
Upside: +285.21%
Revolution Medicines
Aug 10, 2022
Maintains: Outperform
Price Target: $31 → $30
Current: $40.92
Upside: -26.69%
MacroGenics
Aug 9, 2022
Maintains: Outperform
Price Target: $15 → $12
Current: $3.03
Upside: +296.04%
Aug 9, 2022
Maintains: Outperform
Price Target: $13 → $14
Current: $0.59
Upside: +2,285.01%
Jun 3, 2022
Maintains: Outperform
Price Target: $25 → $26
Current: $5.33
Upside: +387.80%
May 11, 2022
Maintains: Outperform
Price Target: $101 → $95
Current: $27.24
Upside: +248.75%
May 9, 2022
Maintains: Market Perform
Price Target: $2 → $3
Current: $0.58
Upside: +415.02%
Feb 25, 2022
Maintains: Outperform
Price Target: $41 → $28
Current: $7.69
Upside: +264.11%
Aug 5, 2021
Maintains: Outperform
Price Target: $57 → $53
Current: $18.83
Upside: +181.47%